CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
Ruihao Huang, Qin Wen, Xi Zhang
Abstract
Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been made in NK cell engineering, target design and combination with other agents to treat relapsed or refractory hematological malignancies, especially acute myeloid leukemia and multiple myeloma. This correspondence summarizes the preclinical and clinical updates for universal CAR-NK cell therapy reported at the ASH 2022 annual meeting.
Topics & Concepts
Chimeric antigen receptorHematologyMedicineMultiple myelomaMyeloid leukemiaRefractory (planetary science)ImmunologyCell therapyOncologyCancer researchImmunotherapyInternal medicineCellCancerBiologyAstrobiologyGeneticsImmune Cell Function and InteractionCAR-T cell therapy researchHematopoietic Stem Cell Transplantation